Commerzbank lowered shares of Smith & Nephew (NYSE:SNN) from a buy rating to a hold rating in a report issued on Monday, The Fly reports.

A number of other research firms have also commented on SNN. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Smith & Nephew in a report on Friday, January 22nd. Canaccord Genuity cut their target price on Smith & Nephew from $55.00 to $53.00 and set a buy rating on the stock in a research note on Friday. Sanford C. Bernstein upgraded Smith & Nephew from a market perform rating to an outperform rating and set a $46.50 target price for the company in a research report on Friday, December 18th. Zacks Investment Research cut Smith & Nephew from a hold rating to a sell rating in a research note on Saturday, October 31st. Finally, Berenberg Bank reissued a buy rating on shares of Smith & Nephew in a research note on Wednesday, January 20th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $47.17.

Smith & Nephew stock opened at $40.04 on Monday. The company has a market cap of $17.56 billion, a PE ratio of 19.63, a PEG ratio of 4.91 and a beta of 0.70. The company has a current ratio of 2.18, a quick ratio of 1.04 and a debt-to-equity ratio of 0.50. Smith & Nephew has a 1 year low of $26.07 and a 1 year high of $49.29. The company’s 50-day moving average is $43.50 and its two-hundred day moving average is $40.72.

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 12th. Stockholders of record on Tuesday, April 6th will be issued a $0.462 dividend. This represents a dividend yield of 1.8%. The ex-dividend date is Monday, April 5th. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.28. Smith & Nephew’s dividend payout ratio is 27.45%.

Large investors have recently modified their holdings of the stock. Voloridge Investment Management LLC lifted its position in Smith & Nephew by 100.4% in the 4th quarter. Voloridge Investment Management LLC now owns 78,428 shares of the medical equipment provider’s stock valued at $3,307,000 after acquiring an additional 39,301 shares in the last quarter. Advisor Partners LLC raised its stake in shares of Smith & Nephew by 38.6% in the 4th quarter. Advisor Partners LLC now owns 8,517 shares of the medical equipment provider’s stock valued at $359,000 after purchasing an additional 2,370 shares during the period. Mariner LLC lifted its holdings in shares of Smith & Nephew by 30.0% in the fourth quarter. Mariner LLC now owns 102,859 shares of the medical equipment provider’s stock valued at $4,338,000 after purchasing an additional 23,719 shares in the last quarter. Endurant Capital Management LP acquired a new position in shares of Smith & Nephew during the fourth quarter worth about $7,554,000. Finally, Captrust Financial Advisors grew its holdings in shares of Smith & Nephew by 19.6% during the fourth quarter. Captrust Financial Advisors now owns 31,014 shares of the medical equipment provider’s stock worth $1,308,000 after buying an additional 5,072 shares in the last quarter. Institutional investors and hedge funds own 8.91% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

Recommended Story: How do buyers and sellers choose a strike price?

The Fly

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.